NASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis $17.82 -0.55 (-2.99%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cidara Therapeutics Stock (NASDAQ:CDTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cidara Therapeutics alerts:Sign Up Key Stats Today's Range$17.68▼$18.4250-Day Range$17.85▼$24.9052-Week Range$10.00▼$28.42Volume34,275 shsAverage Volume68,147 shsMarket Capitalization$195.18 millionP/E RatioN/ADividend YieldN/APrice Target$39.14Consensus RatingBuy Company OverviewCidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Read More… Remove Ads Cidara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreCDTX MarketRank™: Cidara Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 126th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCidara Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cidara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cidara Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.24% of the float of Cidara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently increased by 21.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.85 Percentage of Shares Shorted4.24% of the float of Cidara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently increased by 21.91%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.34 News SentimentCidara Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cidara Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CDTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,477.00 in company stock.Percentage Held by InsidersOnly 7.64% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.82% of the stock of Cidara Therapeutics is held by institutions.Read more about Cidara Therapeutics' insider trading history. Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CDTX Stock News HeadlinesInsider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) COO Sells 1,664 Shares of StockMarch 14, 2025 | insidertrades.comCidara Therapeutics (NASDAQ:CDTX) Share Price Crosses Above Fifty Day Moving Average - Time to Sell?April 2 at 2:57 AM | americanbankingnews.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.April 3, 2025 | Brownstone Research (Ad)Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)April 1 at 4:56 PM | globenewswire.comCidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1 at 4:19 PM | globenewswire.comElicio Therapeutics appoints Preetam Shah as chief strategy, financial officerMarch 24, 2025 | markets.businessinsider.comCidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and ResponseMarch 19, 2025 | globenewswire.comCidara Therapeutics to present on CD388 at ICAR 2025March 19, 2025 | markets.businessinsider.comSee More Headlines CDTX Stock Analysis - Frequently Asked Questions How have CDTX shares performed this year? Cidara Therapeutics' stock was trading at $26.88 at the beginning of 2025. Since then, CDTX stock has decreased by 31.7% and is now trading at $18.37. View the best growth stocks for 2025 here. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its earnings results on Thursday, March, 6th. The biotechnology company reported ($5.38) EPS for the quarter, missing the consensus estimate of ($5.28) by $0.10. Cidara Therapeutics had a negative net margin of 289.05% and a negative trailing twelve-month return on equity of 69.64%. When did Cidara Therapeutics' stock split? Cidara Therapeutics shares reverse split on the morning of Wednesday, April 24th 2024. The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. How do I buy shares of Cidara Therapeutics? Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Meta Platforms (META), VBI Vaccines (VBIV), SCYNEXIS (SCYX), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings3/06/2025Today4/03/2025Next Earnings (Estimated)4/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDTX CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$39.14 High Stock Price Target$46.00 Low Stock Price Target$33.00 Potential Upside/Downside+113.1%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($30.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,930,000.00 Net Margins-289.05% Pretax Margin-514.62% Return on Equity-69.64% Return on Assets-33.73% Debt Debt-to-Equity RatioN/A Current Ratio3.54 Quick Ratio3.54 Sales & Book Value Annual Sales$1.28 million Price / Sales157.81 Cash FlowN/A Price / Cash FlowN/A Book Value($1.82) per share Price / Book-10.09Miscellaneous Outstanding Shares10,953,000Free Float6,509,000Market Cap$201.21 million OptionableNo Data Beta0.89 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CDTX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.